These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12401680)

  • 1. Novel endpoints and design of early clinical trials.
    Parulekar WR; Eisenhauer EA
    Ann Oncol; 2002; 13 Suppl 4():139-43. PubMed ID: 12401680
    [No Abstract]   [Full Text] [Related]  

  • 2. An overview of pharmacoepidemiology.
    Wertheimer AL; Andrews KB
    Pharm World Sci; 1995 May; 17(3):61-6. PubMed ID: 7550051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel methodologic approaches to phase I, II, and III trials.
    Yeatts SD
    Stroke; 2013 Jun; 44(6 Suppl 1):S116-8. PubMed ID: 23709704
    [No Abstract]   [Full Text] [Related]  

  • 4. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
    Sarzotti-Kelsoe M; Cox J; Cleland N; Denny T; Hural J; Needham L; Ozaki D; Rodriguez-Chavez IR; Stevens G; Stiles T; Tarragona-Fiol T; Simkins A
    PLoS Med; 2009 May; 6(5):e1000067. PubMed ID: 19536325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
    Ratain MJ; Mick R; Schilsky RL; Siegler M
    J Natl Cancer Inst; 1993 Oct; 85(20):1637-43. PubMed ID: 8411243
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical shortcomings in licensing applications.
    Lewis JA; Facey KM
    Stat Med; 1998 Aug 15-30; 17(15-16):1663-73. PubMed ID: 9749438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 9. Reinventing clinical trials.
    Allison M
    Nat Biotechnol; 2012 Jan; 30(1):41-9. PubMed ID: 22231093
    [No Abstract]   [Full Text] [Related]  

  • 10. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What was wrong and might now go right with clinical trials for lupus?
    Merrill JT
    Curr Rheumatol Rep; 2009 Aug; 11(4):235-7. PubMed ID: 19691925
    [No Abstract]   [Full Text] [Related]  

  • 14. Designing randomised trials: both large and small trials are needed.
    Stenning SP; Parmar MK
    Ann Oncol; 2002; 13 Suppl 4():131-8. PubMed ID: 12401679
    [No Abstract]   [Full Text] [Related]  

  • 15. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
    Chang SM; Reynolds SL; Butowski N; Lamborn KR; Buckner JC; Kaplan RS; Bigner DD
    Neuro Oncol; 2005 Oct; 7(4):425-34. PubMed ID: 16212807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Missing data from mesothelioma study.
    Aelony Y
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):442-3. PubMed ID: 12579130
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase III trials of targeted anticancer therapies: redesigning the concept.
    Ocana A; Amir E; Vera-Badillo F; Seruga B; Tannock IF
    Clin Cancer Res; 2013 Sep; 19(18):4931-40. PubMed ID: 23881926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of oncology clinical trials: a review.
    Ananthakrishnan R; Menon S
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):144-53. PubMed ID: 23623356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.